Ganitumab failure in pancreatic cancer another setback for Amgen/Takeda alliance
This article was originally published in Scrip
Amgen and its Japanese development partner Takeda have halted the GAMMA Phase III multinational trial with ganitumab (AMG 479), after an interim analysis showed that the monoclonal antibody was likely to miss its overall survival primary endpoint in the pancreatic cancer study.
You may also be interested in...
Novel antifungal T-2307, discovered by FUJIFILM Toyama, works by selectively disrupting mitochondrial function. Excelra and Maruho team up to repurpose existing drugs.
Diversified Japanese giant to launch tender for Danish transplant drug specialist as it looks to build US operations for health care business. Lundbeck and Novo Nordisk among investors that will see an exit.